<DOC>
	<DOC>NCT00919737</DOC>
	<brief_summary>The purpose of this study is to evaluate whether NPC-08 is safety and efficacy in the treatment of newly-diagnosed malignant glioma and recurrent glioblastoma multiforme.</brief_summary>
	<brief_title>Study of NPC-08 is to Treat for Newly-Diagnosed Malignant Glioma and Recurrent Glioblastoma Multiforme</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<criteria>Male or female, aged between 18 and 65 years; Radiographic evidence on cranial MRI of a single contrastenhancing unilateral supratentorial cerebral tumor; Karnofsky Performance Score of 60 or higher; Willing to practice an effective method of birth control for at least 12 months after wafer implantation surgery; More than one focus of tumor or tumor crossing the midline, as assessed by coronal cranial MRI scan; Prior radiotherapy to the brain; Prior chemotherapy for the malignant glioma before the baseline evaluation, or patients who were being treated with chemotherapeutic agents; Known hypersensitivity to nitrosoureas; Participation in any other investigational protocol in the previous 6 months for any type of malignancy;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>NPC-08</keyword>
	<keyword>carmustine</keyword>
	<keyword>nitrosourea</keyword>
	<keyword>safety</keyword>
</DOC>